Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-12-28 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
关于使用部分闲置自有资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Beijing Northland Biotechnology Co., Ltd. regarding the progress of using part of its idle own funds for entrusted wealth management. It includes specifics about the authorized entrusted wealth management, amounts, counterparties, product types, investment terms, risk controls, and cumulative amounts. The document is a regulatory disclosure about financing activities related to the company's capital management, specifically the use of idle funds for financial products. It is not a full financial report, audit, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the transactions and risk controls. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2025-12-28 Chinese
部分募投项目延期公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the delay of certain fundraising investment projects by Beijing Northland Biotech Co., Ltd. It details the use of funds raised through a share issuance, the progress of fund usage, reasons for project delays, and the company's decision-making process including board approvals. The document does not contain full financial statements or detailed financial performance data, but rather focuses on the status and management of capital raised and its investment projects. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is under 5,000 characters and is not merely an announcement of a report publication, but a substantive update on fundraising project progress and changes.
2025-12-25 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司部分募投项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from Zhongtai Securities regarding the delay of certain fundraising investment projects by Beijing Nuosiland Biotechnology Co., Ltd. It details the fundraising amount, usage, project delay reasons, revised timelines, and the approval process by the board. The document is focused on the status and management of fundraising projects and compliance with regulatory requirements. It is not a full financial report, earnings release, or audit report. It is also not a simple announcement of a report publication but a detailed verification opinion related to fundraising project delays. This fits best under Capital/Financing Update (CAP) as it concerns updates on fundraising activities and capital usage.
2025-12-25 Chinese
第六届董事会第二十五次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 25th meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It details the meeting's attendance, the agenda, and the voting results on a proposal regarding the postponement of a fundraising project. There is no financial data, earnings information, or detailed report content. The document is clearly a Board/Management Information announcement about board meeting decisions and resolutions, not a full report or financial statement. Therefore, the appropriate classification is 'MANG' (Board/Management Information). The document length is short and focused on board decisions, consistent with this category.
2025-12-25 Chinese
关于子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Northland Biotechnology Co., Ltd. regarding its subsidiary receiving a High-Tech Enterprise Certificate, which grants tax benefits. It includes details about the certificate, its validity, and the impact on the company. The document is short (685 characters) and focuses on a regulatory or compliance announcement rather than financial results, management changes, or detailed reports. It does not contain financial statements or detailed analysis. It is not an annual report, interim report, earnings release, or any detailed financial or governance report. It is also not a voting result, capital change, or legal proceeding. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-12-16 Chinese
关于使用部分闲置自有资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Northland Biotechnology Co., Ltd. regarding the progress of using part of its idle own funds for entrusted wealth management. It details the authorization, amounts, counterparties, risk controls, and investment products involved. The document is a disclosure about the company's financing activities related to entrusted wealth management products, including amounts invested, expected returns, and risk management. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an annual or interim report, nor is it a call transcript or AGM material. It is an update on the company's capital usage and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5517 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-12-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.